Is obesity a risk factor for vaccine non-responsiveness?
Understanding the link between vaccine immunogenicity and efficacy is currently a major focus in HIV research. Consequently, recent developments in the HIV-1 vaccine field have led to a closer look at immune responses to known efficacious vaccines. We undertook a study to explore clinical predictors...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3859613?pdf=render |
id |
doaj-a0f507a22b504b0490888d852ad0f93e |
---|---|
record_format |
Article |
spelling |
doaj-a0f507a22b504b0490888d852ad0f93e2020-11-24T21:56:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8277910.1371/journal.pone.0082779Is obesity a risk factor for vaccine non-responsiveness?Katherine M YoungClive M GrayLinda-Gail BekkerUnderstanding the link between vaccine immunogenicity and efficacy is currently a major focus in HIV research. Consequently, recent developments in the HIV-1 vaccine field have led to a closer look at immune responses to known efficacious vaccines. We undertook a study to explore clinical predictors of vaccine efficacy following recombinant hepatitis B (rHBV) vaccination in a cohort of HIV-uninfected, hepatitis B virus naïve women living in a peri-urban setting in Cape Town. Our aim was to define host biological risk factors associated with lack of vaccine uptake. We found a significant association (p=0.009) between body mass index (BMI) and lack of vaccine-specific IgG titre (<10 mIU/mL). Obese individuals (BMI ≥ 30 kg/m(2)) were significantly more likely to be non-responders following 2 rHBV vaccine doses (Adjusted Odds Ratio of 8.75; p=0.043). There was no observed association between vaccine responses and age, method of contraception or time from vaccination to antibody measurement. These data suggest that obesity-associated factors interfere with vaccine immunogenicity and possible efficacy.http://europepmc.org/articles/PMC3859613?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Katherine M Young Clive M Gray Linda-Gail Bekker |
spellingShingle |
Katherine M Young Clive M Gray Linda-Gail Bekker Is obesity a risk factor for vaccine non-responsiveness? PLoS ONE |
author_facet |
Katherine M Young Clive M Gray Linda-Gail Bekker |
author_sort |
Katherine M Young |
title |
Is obesity a risk factor for vaccine non-responsiveness? |
title_short |
Is obesity a risk factor for vaccine non-responsiveness? |
title_full |
Is obesity a risk factor for vaccine non-responsiveness? |
title_fullStr |
Is obesity a risk factor for vaccine non-responsiveness? |
title_full_unstemmed |
Is obesity a risk factor for vaccine non-responsiveness? |
title_sort |
is obesity a risk factor for vaccine non-responsiveness? |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Understanding the link between vaccine immunogenicity and efficacy is currently a major focus in HIV research. Consequently, recent developments in the HIV-1 vaccine field have led to a closer look at immune responses to known efficacious vaccines. We undertook a study to explore clinical predictors of vaccine efficacy following recombinant hepatitis B (rHBV) vaccination in a cohort of HIV-uninfected, hepatitis B virus naïve women living in a peri-urban setting in Cape Town. Our aim was to define host biological risk factors associated with lack of vaccine uptake. We found a significant association (p=0.009) between body mass index (BMI) and lack of vaccine-specific IgG titre (<10 mIU/mL). Obese individuals (BMI ≥ 30 kg/m(2)) were significantly more likely to be non-responders following 2 rHBV vaccine doses (Adjusted Odds Ratio of 8.75; p=0.043). There was no observed association between vaccine responses and age, method of contraception or time from vaccination to antibody measurement. These data suggest that obesity-associated factors interfere with vaccine immunogenicity and possible efficacy. |
url |
http://europepmc.org/articles/PMC3859613?pdf=render |
work_keys_str_mv |
AT katherinemyoung isobesityariskfactorforvaccinenonresponsiveness AT clivemgray isobesityariskfactorforvaccinenonresponsiveness AT lindagailbekker isobesityariskfactorforvaccinenonresponsiveness |
_version_ |
1725857302083272704 |